Tipifarnib

Generic Name: Tipifarnib

Drug Type: Small Molecule

Chemical Formula: C_₂₇H_₂₂Cl_₂N_₄O

CAS Number: 192185-72-1

Unique Ingredient Identifier: MAT637500A

Background: Tipifarnib (R-115777) is a substance that is being studied in the treatment of acute myeloid leukemia (AML) and other types of cancer. It belongs to the family of drugs called farnesyltransferase inhibitors. It is also called Zarnestra. In June 2005, the FDA issued a Not Approvable Letter for Zarnestra.

Indication: Investigated for use/treatment in colorectal cancer, leukemia (myeloid), pancreatic cancer, and solid tumors.

Clinical Trials

R115777 in Treating Patients With Relapsed Small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

First Posted Date: 2004-06-18

Last Posted Date: 2012-11-09

Lead Sponsor: NYU Langone Health

Registration Number: NCT00005041

Locations: 🇺🇸
Kaplan Cancer Center, New York, New York, United States

Tipifarnib and Erlotinib Hydrochloride in Treating Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Solid Neoplasm

Interventions: Drug: Erlotinib Hydrochloride
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Drug: Tipifarnib

First Posted Date: 2004-06-11

Last Posted Date: 2018-05-18

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 29

Registration Number: NCT00085553

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Tipifarnib and Fulvestrant in Hormone Receptor-Positive Metastatic Breast Cancer

Phase 2

Completed

Conditions: Estrogen Receptor-positive Breast Cancer
Recurrent Breast Cancer
Stage IIIB Breast Cancer
Stage IIIC Breast Cancer
Stage IV Breast Cancer

Interventions: Drug: fulvestrant
Drug: tipifarnib

First Posted Date: 2004-05-19

Last Posted Date: 2018-11-01

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 33

Registration Number: NCT00082810

Locations: 🇺🇸
Montefiore Medical Center, Bronx, New York, United States

Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma

Phase 2

Completed

Conditions: Anaplastic Large Cell Lymphoma
Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
Nodal Marginal Zone Lymphoma
Recurrent Adult T-Cell Leukemia/Lymphoma
Recurrent Grade 2 Follicular Lymphoma
Recurrent Grade 3 Follicular Lymphoma
Recurrent Mantle Cell Lymphoma
Recurrent Small Lymphocytic Lymphoma
Splenic Marginal Zone Lymphoma

Interventions: Other: Laboratory Biomarker Analysis
Drug: Tipifarnib

First Posted Date: 2004-05-19

Last Posted Date: 2020-04-13

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 93

Registration Number: NCT00082888

Locations: 🇺🇸
University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa, United States
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer

Phase 1

Completed

Conditions: Cancer

Interventions: Biological: trastuzumab
Drug: tipifarnib

First Posted Date: 2004-04-26

Last Posted Date: 2013-02-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 24

Registration Number: NCT00005842

Locations: 🇺🇸
Institute for Drug Development, San Antonio, Texas, United States
🇺🇸
Brooke Army Medical Center, Fort Sam Houston, Texas, United States

S9924 R115777 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Phase 2

Completed

Conditions: Pancreatic Cancer

Interventions: Drug: R115777

First Posted Date: 2004-04-26

Last Posted Date: 2015-11-17

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 58

Registration Number: NCT00005832

Locations: 🇺🇸
CCOP - Montana Cancer Consortium, Billings, Montana, United States
🇺🇸
CCOP - Columbus, Columbus, Ohio, United States
🇺🇸
CCOP - Upstate Carolina, Spartanburg, South Carolina, United States

and more 11 locations

R115777 in Treating Patients With Recurrent or Metastatic Non-small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

First Posted Date: 2004-04-20

Last Posted Date: 2011-08-04

Lead Sponsor: Mayo Clinic

Registration Number: NCT00005989

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States

S9923 R115777 in Treating Patients With Advanced Colorectal Cancer

Phase 2

Completed

Conditions: Colorectal Cancer

Interventions: Drug: R115777

First Posted Date: 2004-04-12

Last Posted Date: 2012-06-14

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 62

Registration Number: NCT00005833

Locations: 🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
Veterans Affairs Outpatient Clinic - Martinez, Martinez, California, United States
🇺🇸
CCOP - Central Illinois, Decatur, Illinois, United States

and more 9 locations

R115777 in Treating Patients With Advanced Bladder Cancer

Phase 2

Completed

Conditions: Bladder Cancer
Transitional Cell Cancer of the Renal Pelvis and Ureter

First Posted Date: 2004-04-02

Last Posted Date: 2013-12-04

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Registration Number: NCT00006376

Locations: 🇺🇸
UCSF Cancer Center and Cancer Research Institute, San Francisco, California, United States
🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

R115777 in Treating Patients With Progressive, Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

Phase 2

Completed

Conditions: Prostate Cancer

First Posted Date: 2004-03-16

Last Posted Date: 2013-07-11

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 7

Registration Number: NCT00005848

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy